Management of AL amyloidosis in 2020

Giovanni Palladini, Paolo Milani, and Giampaolo Merlini

In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the form of amyloid fibrils. Organ involvement determines the clinical manifestations, but symptoms are usually recognized late. Patients with disease diagnosed at advanced stages, particularly when heart involvement is present, are at high risk of death within a few months. However, symptoms are always preceded by a detectable monoclonal gammopathy and by elevated biomarkers of organ involvement, and hematologists can screen subjects who have known monoclonal gammopathy for amyloid organ dysfunction and damage, allowing for a presymptomatic diagnosis. Discriminating patients with other forms of amyloidosis is difficult but necessary, and tissue typing with adequate technology available at referral centers, is mandatory to confirm AL amyloidosis. Treatment targets the underlying clone and should be risk adapted to rapidly administer the most effective therapy patients can safely tolerate. In approximately one-fifth of patients, autologous stem cell transplantation can be considered up front or after bortezomib-based conditioning. Bortezomib can improve the depth of response after transplantation and is the backbone of treatment of patients who are not eligible for transplantation. The daratumumab + bortezomib combination is emerging as a novel standard of care in AL amyloidosis. Treatment should be aimed at achieving early and profound hematologic response and organ response in the long term. Close monitoring of hematologic response is vital to shifting nonresponders to rescue treatments. Patients with relapsed/refractory disease are generally treated with immune-modulatory drugs, but daratumumab is also an effective option. (Blood. 2020;136(23):2620-2627)

Clinical case

A 65-year-old man with a history of hypertension developed worsening exertional dyspnea over the course of 6 months. During the previous 6 months he had progressively reduced and eventually discontinued his angiotensin-converting enzyme inhibitor because of “resolution” of hypertension. His cardiologist suspected amyloid heart involvement based on echocardiography and recommended cardiac magnetic resonance (CMR) imaging, which showed late gadolinium enhancement. 99mTc-hydroxy-methylene-diphosphonate scintigraphy revealed cardiac uptake. A diagnosis of transthyretin (ATTR) amyloidosis was presumed. The patient was referred to a medical geneticist to rule out hereditary amyloidoses and to a hematologist to rule out light chain (AL) amyloidosis. Genetic testing for hereditary ATTR amyloidosis was negative. Immunofixation revealed κ Bence Jones protein. The patient was then referred to our center for amyloid typing and presented with New York Heart Association class III (NYHA class III) heart failure and postural hypotension. The κ-free light chain (FLC) concentration was 206 mg/L (ratio [FLCR], 10.3, and differential FLC [dFLC], 186 mg/L); bone marrow plasma cell (PC) infiltrate was 12% without chromosomal abnormalities; blood count, calcium, and liver function test results were normal; estimated glomerular filtration rate (eGFR) was 48 mL/min; proteinuria was 2.8 g per 24 hours, predominantly albumin; N-terminal proa1-antitrypsin type-B (NT-proBNP) was 10,625 ng/L (upper reference limit [url], 227 ng/L); and cardiac troponin I (cTnI) was 124 ng/L (url, 44 ng/L). A computed tomographic (CT) scan showed no bone lesions. Abdominal fat aspiration showed amyloid deposits typed as AL κ by immunoelectron microscopy (IEM). A diagnosis of AL amyloidosis with cardiac (stage IIIb) and renal (stage II) involvement was established. The patient received attenuated treatment with cyclophosphamide, bortezomib, and dexamethasone in subintensive care. Treatment was associated with fluid retention. Nevertheless, he received the second cycle as an outpatient. After 2 cycles, very good partial response (VGPR) was reached (dFLC, 11 mg/L; FLCR, 2.1; and persistence of κ Bence Jones protein), with improvement of markers of cardiac (NT-proBNP, 7225 ng/L) and renal (proteinuria, 1.7 g per 24 hours) involvement. Two more cycles were administered that were accompanied by fluid retention but did not improve hematologic (dFLC, 9 mg/L; FLCR, 2.0; and persistence of κ Bence Jones protein) and organ (NT-proBNP, 6792 ng/L; proteinuria, 1.5 g per 24 hours) response. Heart failure improved (NYHA class II), and treatment was discontinued based on the patient’s preference. Follow-up testing was scheduled every 3 months. After 15 months, markers of organ involvement were stable (NT-proBNP, 7471 ng/L; proteinuria, 1.4 g per 24 hours), but FLC increased (dFLC, 98 mg/L; FLCR, 5.9). The patient was treated with daratumumab, bortezomib, and dexamethasone. After 1 week, VGPR was reestablished (dFLC, 8 mg/L; FLCR, 1.8; and persistence of κ Bence Jones protein),
Heart involvement is the major determinant of survival. Preclinical gain 1(q21) is associated with poorer results with oral melphalan.3-5 with bortezomib and immunomodulatory drugs (IMiDs), whereas Patients whose PC clones harbor t(11;14) have a worse outcome that usually is managed with local treatment.1 In systemic AL gastrointestinal tracts, with local symptoms and a benign course nodules to develop in the skin and in the respiratory, urinary, and lung tissue. In contrast, systemic involvement of LCs causes organ dysfunction and damage and forms amyloid fibrils in tissues. In contrast, localized deposition of LCs causes nodules to develop in the skin and in the respiratory, urinary, and gastrointestinal tracts, with local symptoms and a benign course. However, cardiac and renal involvement is often irreversible. However, cardiac and renal amyloidosis can be detected by NT-proBNP and albuminuria in whom elevated NT-proBNP is found. However, the cost effectiveness of this approach is unknown. A diagnostic inflammatory test in subjects with MGUS findings suggest and after 4 months, complete response (CR) was attained (dFLC, 3 mg/L; FLCR, 1.2; and negative serum and urine immunofixation) with cardiac response (NT-proBNP, 2809 ng/L). Twelve months later, CR had been maintained, and minimal residual disease (MRD) was not detectable by next-generation flow cytometry.

**Introduction**

In systemic AL amyloidosis a PC clone, or, less frequently, a lymphoplasmacytic or marginal zone lymphoma, produces a toxic LC that causes organ dysfunction and damage and forms amyloid fibrils in tissues. In contrast, localized deposition of LCs causes organ dysfunction and damage and forms amyloid fibrils in tissues. In contrast, localized deposition of LCs causes organ dysfunction and damage and forms amyloid fibrils in tissues.

Heart involvement is the major determinant of survival. Preclinical models and clinical observation of rapid cardiac improvement after a decline in LC concentration disclosed a direct cardiotoxic effect of the circulating precursor.6,7 The severity of organ involvement is assessed with biomarkers combined in accurate staging systems (Table 1). 8-12 Survival also depends on hematologic response (HR), because LCs are the agents directly causing organ dysfunction. If the disease is not treated promptly and effectively, organ dysfunction progresses and ultimately leads to death. Recent trials of immunotherapies targeting the amyloid deposits (the anti-fibril antibody NEOD001 and the combination of the amyloid P component [which targets small-molecule miridesap], and dezamizumab) failed. Only one anti-amyloid fibril antibody CAEL-101 is still under evaluation (www.clinicaltrials.gov #NCT04304144). Current treatments target the underlying clone and are aimed at suppressing the production of LCs to restore organ function and extend survival. Advanced organ involvement, particularly cardiac, is associated with early death and causes extreme frailty limiting the delivery of effective therapy. In recent years, advancements in biomarker-based risk stratification and monitoring of response and novel anti-PC agents has improved outcomes. Early and correct diagnosis is the prerequisite to beneficial use of these tools.

**Diagnostic workup**

The clinical presentation of AL amyloidosis depends on organ involvement, and it is protean and deceitful. Symptoms are often misinterpreted and recognized late. When they appear, organ involvement is often irreversible. However, cardiac and renal amyloidosis can be detected by NT-proBNP and albuminuria before overt heart failure and nephrotic syndrome arise. Moreover, a monoclonal component can be found at least 4 years before diagnosis.13 Therefore, hematologists can intercept, diagnose, and treat patients during the presymptomatic stage, by including biomarkers of organ involvement in the monitoring panel of subjects with monoclonal gammopathy of undetermined significance (MGUS).14 Recent findings suggest that CMR can detect very early cardiac involvement15; hence, CMR may be used as a confirmatory test in subjects with MGUS in whom elevated NT-proBNP is found. However, the cost effectiveness of this approach is unknown. A diagnostic flowchart for AL amyloidosis is reported in Figure 1.

<table>
<thead>
<tr>
<th>Staging system</th>
<th>Markers and thresholds</th>
<th>Stages</th>
<th>Outcomes*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiac (NT-proBNP based)</strong></td>
<td>NT-proBNP &gt;332 ng/L cTnT &gt;0.035 ng/mL (or cTnl &gt;0.01 ng/mL)</td>
<td>I. No markers above the cutoff II. One marker above the cutoff IIIa. Both markers above the cutoff and NT-proBNP &lt;8500 ng/L IIIb. Both markers above the cutoff and NT-proBNP ≥8500 ng/L</td>
<td>I. Median survival not reached, 57% with 10-y survival II. Median survival 67 mo IIIa. Median survival 15 mo IIIb. Median survival 4 mo</td>
</tr>
<tr>
<td><strong>Cardiac (BNP based)</strong></td>
<td>BNP &gt;81 ng/L cTnl &gt;0.1 ng/mL</td>
<td>I. No markers above the cutoff II. One marker above the cutoff IIIa. Both markers above the cutoff and BNP &lt;700 ng/L IIIb. Both markers above the cutoff and BNP ≥700 ng/L</td>
<td>I. Median survival 151 mo, 57% with 10-y survival II. Median survival 53 mo III. Median survival 13 mo IV. Median survival 4 mo</td>
</tr>
<tr>
<td><strong>Revised Mayo Clinic</strong></td>
<td>NT-proBNP &gt;1800 ng/L cTnT &gt;0.025 ng/mL dFLC &gt;180 mg/L</td>
<td>I. 0 markers above the cutoff II. 1 marker above the cutoff III. 2 markers above the cutoff IV. 3 markers above the cutoff</td>
<td>I. Median survival not reached, 57% with 10-y survival II. Median survival 69 mo III. Median survival 16 mo IV. Median survival 6 mo</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>eGFR &lt;50 mL/min per 1.73 m² proteinuria &gt;5 g per 24 h</td>
<td>I. Both eGFR above and proteinuria above the cutoffs II. Either eGFR below or proteinuria above the cutoffs III. Both eGFR below and proteinuria above the cutoffs</td>
<td>I. 1% risk of dialysis at 2 y II. 12% risk of dialysis at 2 y III. 48% risk of dialysis at 2 y</td>
</tr>
</tbody>
</table>

*Observed in 1378 patients with AL amyloidosis newly diagnosed at the Pavia Amyloidosis Research and Treatment Center from 2004 through 2018.

dFLC, difference between involved (amyloidogenic) and uninvolved circulating free light chain.

Table 1. Staging systems for AL amyloidosis

<table>
<thead>
<tr>
<th>Staging system</th>
<th>Markers and thresholds</th>
<th>Stages</th>
<th>Outcomes*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiac (NT-proBNP based)</strong></td>
<td>NT-proBNP &gt;332 ng/L cTnT &gt;0.035 ng/mL (or cTnl &gt;0.01 ng/mL)</td>
<td>I. No markers above the cutoff II. One marker above the cutoff IIIa. Both markers above the cutoff and NT-proBNP &lt;8500 ng/L IIIb. Both markers above the cutoff and NT-proBNP ≥8500 ng/L</td>
<td>I. Median survival not reached, 57% with 10-y survival II. Median survival 67 mo IIIa. Median survival 15 mo IIIb. Median survival 4 mo</td>
</tr>
<tr>
<td><strong>Cardiac (BNP based)</strong></td>
<td>BNP &gt;81 ng/L cTnl &gt;0.1 ng/mL</td>
<td>I. No markers above the cutoff II. One marker above the cutoff IIIa. Both markers above the cutoff and BNP &lt;700 ng/L IIIb. Both markers above the cutoff and BNP ≥700 ng/L</td>
<td>I. Median survival 151 mo, 57% with 10-y survival II. Median survival 53 mo III. Median survival 13 mo IV. Median survival 4 mo</td>
</tr>
<tr>
<td><strong>Revised Mayo Clinic</strong></td>
<td>NT-proBNP &gt;1800 ng/L cTnT &gt;0.025 ng/mL dFLC &gt;180 mg/L</td>
<td>I. 0 markers above the cutoff II. 1 marker above the cutoff III. 2 markers above the cutoff IV. 3 markers above the cutoff</td>
<td>I. Median survival not reached, 57% with 10-y survival II. Median survival 69 mo III. Median survival 16 mo IV. Median survival 6 mo</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>eGFR &lt;50 mL/min per 1.73 m² proteinuria &gt;5 g per 24 h</td>
<td>I. Both eGFR above and proteinuria above the cutoffs II. Either eGFR below or proteinuria above the cutoffs III. Both eGFR below and proteinuria above the cutoffs</td>
<td>I. 1% risk of dialysis at 2 y II. 12% risk of dialysis at 2 y III. 48% risk of dialysis at 2 y</td>
</tr>
</tbody>
</table>

*Observed in 1378 patients with AL amyloidosis newly diagnosed at the Pavia Amyloidosis Research and Treatment Center from 2004 through 2018.

dFLC, difference between involved (amyloidogenic) and uninvolved circulating free light chain.
Screening for pre-symptomatic amyloid organ involvement in patients with MGUS and abnormal FLC ratio

At diagnosis of MGUS and at each follow-up visit check:
- NT-proBNP (or BNP)
- albuminuria
- alkaline phosphatase

Patients presenting with signs and symptoms of amyloid organ involvement

Signs and symptoms of amyloid organ involvement (often combined)
- heart failure (with preserved EF and increased wall thickness often with low voltages at ECG)
- nephrotic syndrome (proteinuria progressing to renal failure)
- hepatomegaly (with cholestasis)
- “resolution” of hypertension
- (postural) hypotension, syncope
- erectile dysfunction
- peripheral neuropathy (ascending, symmetric, small fibers/axonal)
- gastrointestinal mobility alterations
- fatigue
- weight loss
- peribortal purpura
- macroglossia
- submandibular glands swelling

Is a monoclonal component present?
Adequate diagnostic sensitivity requires combination of immunofixation of serum and urine and measurement of FLC.

Yes
No

Diagnostic workup for non-AL amyloidosis:
- cardiac scintigraphy with bone tracers in patients with heart involvement
- DNA testing

Tissue diagnosis
- Abdominal fat (sensitivity ~80% at referral centers), bone marrow (sensitivity ~70%), minor salivary gland (sensitivity ~80%)
- Biopsy of organ involved.

Assessment of clonal disease, organ involvement, staging and risk stratification
- immunofixation of serum and urine and measurement of FLC, BMPC iFISH, skeletal survey;
- NT-proBNP (or BNP), cardiac troponin, ECG, Holter ECG, echocardiography, cardiac MRI;
- 24h proteinuria, creatinine (with eGFR);
- liver function test
- evaluation of comorbidities

Figure 1. Presenting features and diagnostic algorithm for AL amyloidosis. Amyloidosis can be suspected if elevated biomarkers of organ involvement are detected during follow-up of patients with MGUS or if suggestive symptoms arise. The first scenario is ideal and enables early presymptomatic diagnosis. Based on relative rates of progression, appropriate screening programs should detect 1 patient with MGUS progressing to AL amyloidosis for every 7 to 10 who develop multiple myeloma. In patients with MGUS in whom elevated NT-proBNP or BNP is found, cardiac magnetic resonance imaging can be used as a higher specificity confirmatory test. If symptoms of systemic amyloidosis arise in a patient in whom a preexisting monoclonal gammopathy is not known, the first step should be searching for a monoclonal component, particularly if heart involvement is suspected, so as not to delay diagnosis. Only the combination of immunofixation of both serum and urine and FLC measurement grant adequate diagnostic sensitivity to detect amyloidogenic monoclonal proteins. MS-based methods are under investigation. Patients with suspect cardiac amyloidosis without monoclonal components can have an attempted nonbiopsy diagnosis of ATTR amyloidosis with cardiac scintigraphy with bone tracers. Validated tracers are 99mTc-diphosphono-propanodicarboxylic acid, 99mTc-pyrophosphate, and 99mTc-hydroxymethylene diphosphonate. DNA analysis is necessary to differentiate between hereditary and wild-type ATTR amyloidosis and to rule out other rarer hereditary forms. All other patients require a tissue diagnosis. Amyloid deposits can be found in abdominal fat, minor salivary glands, and bone marrow, and most patients can be spared biopsy of the involved organ. However, if amyloidosis is deemed probable, for a prompt start of treatment, organ biopsy should not be deferred. Amyloid deposits are recognized as nonbranching fibrils of 7 to 10 nm in width, detected by light microscopy with green birefringence under polarized light after staining with Congo red or by electron microscopy. The diagnostic sensitivity of abdominal fat aspirate combined with bone marrow or minor salivary gland biopsy is ~90% at referral centers, but the recognition of amyloid deposits is affected by the experience of the pathologist. With a few exceptions (eg, patients with a monoclonal component and peribortal purpura and/or macroglossia, or combination of amyloid heart and renal involvement with albuminuria), the clinical presentation of AL amyloidosis cannot reliably be differentiated from that of other types of systemic amyloidosis. Thus, amyloid tissue typing with adequate technology is mandatory. Standard light microscopy immunohistochemistry does perform satisfactorily, and patients should be referred to specialized centers for typing with adequate technology (immunohistochemistry with custom-made antibodies, IEM, or MS). Accurate clonal studies, biomarker-based staging, and assessment of comorbidities are necessary to design the therapeutic strategy. MRI, magnetic resonance imaging.
A tissue biopsy is always necessary to establish the diagnosis of AL amyloidosis. Notably, other types of systemic amyloidosis can have clinical presentations that overlap that of AL amyloidosis (Table 2). Of these, wild-type transthyretin (ATTRwt) amyloidosis, is the most common. Effective treatments are now available for wild-type and hereditary ATTR amyloidosis, but correct amyloid typing is mandatory. The other, rarer types should not be disregarded. In contrast to AL amyloidosis, the diagnosis of ATTRwt amyloidosis requires tissue typing only in patients in whom a monoclonal component is detected. In the absence of a monoclonal component, a nonbiopsy diagnosis of ATTRwt amyloidosis is possible based on cardiac uptake of bisphosphonate scintigraphy tracers. Patients with cardiac AL amyloidosis usually have no or modest uptake; however, patients may have intense uptake. Moreover, one-fourth to one-third of patients with ATTRwt have a monoclonal component. AL amyloidosis is by far the most rapidly progressing type of cardiac amyloidosis and is the one that benefits most from early initiation of effective therapy. Thus, the first step in the diagnostic workup of cardiac amyloidosis should be searching for monoclonal components. In the present clinical case, a substantial diagnostic delay resulted from deferred testing for PC dyscrasia.

### Table 2. Most common forms of systemic amyloidosis

<table>
<thead>
<tr>
<th>Amyloid type</th>
<th>Precursor protein</th>
<th>Major organ involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Heart (bone tracer uptake)*</td>
</tr>
<tr>
<td>AL amyloidosis (acquired)</td>
<td>Immunoglobulin light chain</td>
<td>+++ (usually absent, can be intense)</td>
</tr>
<tr>
<td>ATTRv amyloidosis (hereditary)</td>
<td>Mutated transthyretin</td>
<td>+++ (usually intense, can be absent in some variants)</td>
</tr>
<tr>
<td>ATTRwt amyloidosis (acquired)</td>
<td>Wild-type transthyretin</td>
<td>+++ (usually intense)</td>
</tr>
<tr>
<td>ApoAI amyloidosis (hereditary)</td>
<td>Mutated apolipoprotein AI</td>
<td>+ (present)</td>
</tr>
<tr>
<td>AA amyloidosis (acquired)</td>
<td>Serum amyloid A protein</td>
<td>+</td>
</tr>
<tr>
<td>ALECT2 (acquired)</td>
<td>Leukocyte chemotactic factor 2</td>
<td>—</td>
</tr>
</tbody>
</table>

In AL amyloidosis, soft tissue involvement can manifest as macroglossia, shoulder pad sign, raccoon eyes, carpal tunnel syndrome, synovial enlargement, and firm, enlarged lymph nodes. In ATTRwt, carpal tunnel and lumbar stenosis are frequently reported. ANS, autonomic nervous system; PNS, peripheral neuropathic involvement; ST, soft tissue; ATTRv, transthyretin amyloidosis variants; AA, serum amyloid A; ApoAI, apolipoprotein AI; ALECT2, leukocyte chemotactic factor 2 amyloidosis.

*Bone tracers validated for the detection of cardiac amyloidosis are $^{99m}$Tc-diphosphono-propanodicarboxylic acid, $^{99m}$Tc-pyrophosphate, and $^{99m}$Tc-hydroxymethylene diphosphonate; ++++, ≥50%; ++, 10%-30%; +, ≤10%; —, rare or not involved.

### Table 3. Validated criteria for HR and organ response

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR</td>
<td>CR (all of the following criteria must be met):</td>
</tr>
<tr>
<td></td>
<td>• Serum and urine immunofixation negative for monoclonal protein</td>
</tr>
<tr>
<td></td>
<td>• Normalized free light chain ratio</td>
</tr>
<tr>
<td></td>
<td>VGPR reduction of dFLC below 40 mg/L</td>
</tr>
<tr>
<td></td>
<td>PR 50% reduction of dFLC</td>
</tr>
<tr>
<td>Organ response</td>
<td>Kidney: a 30% reduction in 24-h urine protein excretion or a drop of proteinuria below 0.5 g per 24 h in the absence of progressive renal insufficiency, defined as a decrease in eGFR to 25% over baseline.</td>
</tr>
<tr>
<td></td>
<td>Heart (NT-proBNP based): reduction of NT-proBNP of 30% and &gt;300 ng/L over the starting value. Baseline NT-proBNP has to be ≥650 ng/L to be measurable.</td>
</tr>
<tr>
<td></td>
<td>Heart (BNP based): reduction of BNP of 30% and &gt;50 ng/L over the starting value. Baseline BNP has to be ≥150 ng/L to be measurable.</td>
</tr>
<tr>
<td>CHOR model</td>
<td>Patients are classified in 2 CHOR groups according to a score based on the HR and organ response criteria</td>
</tr>
<tr>
<td></td>
<td>• Score for HR: CR, 0; VGPR, 1; PR, 2; no response, 3</td>
</tr>
<tr>
<td></td>
<td>• Score for organ response: response in all organs involved, 0; response in at least 1 but not all the organs involved, 1; no organ response, 2.</td>
</tr>
<tr>
<td></td>
<td>CHOR group 1, score 0-3</td>
</tr>
<tr>
<td></td>
<td>CHOR group 2, score 4-5</td>
</tr>
</tbody>
</table>

CHOR, composite hematologic/organ response model; PR, partial response.
Once the diagnosis of AL amyloidosis is established, the characteristics of the underlying clone and the extent and severity of organ involvement should be studied (Figure 1). This information is essential for designing the therapeutic strategy.

**Up-front therapy**

Treatment should be risk adapted, considering the severity of organ involvement, characteristics of the clone, and comorbidities and seeking to deliver the most rapid and effective therapy patients can safely tolerate. Delicate up-front therapy can sometimes trigger early improvement of organ dysfunction, allowing for subsequent, more aggressive treatment. Early and profound reductions of the amyloid LC are associated with the greatest chance of organ improvement, and prolongation of progression-free survival (PFS) and overall (OS) survival. Changes in biomarkers can be used to assess response to therapy according to validated criteria (Table 3). The optimal end point of therapy is still a matter of debate.
matters of debate. Achievement of organ response can indicate that the amyloid LC level has fallen below the concentration needed to sustain organ dysfunction. Organ response can parallel HR, as did in the patient described herein, but it is sometimes delayed. For this reason, assessment of treatment efficacy and a decision to shift to rescue regimens should be based on early HR assessment (3 months after autologous stem cell transplantation [ASCT], 1 to 2 months after nontransplantation therapies). Achievement of organ response and profound clonal response should be the long-term goal of therapy. Individual frailty, age, bone marrow PC infiltration, residual organ dysfunction, and treatment tolerability should be considered to decide whether CR should be pursued. Novel definitions of deep HR are being investigated. The relatively low sensitivity and imprecision of available FLC assays demand novel technologies, such as mass spectrometry (MS)–based detection of monoclonal components and assessment of MRD that await validation in AL amyloidosis.

Accurate risk stratification is crucial in designing the treatment strategy (Figure 2). Approximately 20% of patients with newly diagnosed disease are candidates for ASCT, and more can become eligible after effective up-front therapy. Moreover, pretransplantation induction therapy independently improves PFS. In a large series, 84% of patients attained HR after ASCT (VGPR, 33%; CR, 39%) and the CR rate can increase to ~60% (~40% MRD) with posttransplantation bortezomib-based treatment. OS of patients who reach CR with ASCT is >50% at 15 years.

Most patients with AL amyloidosis are not eligible for ASCT. Oral melphalan + dexamethasone (MDex) has been a standard of care for many years in these subjects. Currently, bortezomib is the backbone of up-front treatment regimens and is combined with Mdx (BMDex) or with cyclophosphamide and dexamethasone (CyBorD). A phase 3 trial in intermediate-risk patients (#NCT01277016) showed that BMDex induces a significantly higher HR rate (81% vs 57%; CR, 23% vs 20%; VGPR 42% vs 20%) than Mdx, with prolonged OS. Cardiac and renal responses were observed in 38% and 44% of cases with BMDex and in 28% and 43% of cases with Mdx, respectively. In a large, unselected, retrospective series, overall HR rate in response to CyBorD was 65% (CR, 25%; VGPR, 24%), with cardiac response in 33% of patients and renal response in 15%. A phase 3 trial comparing CyBorD with CyBorD+subcutaneous daratumumab has been completed (#NCT03201965). The uncontrolled safety assessment

- Salt restriction and diuretics
- Fitted elastic leotards and midodrine for hypotension
- Patients with recurrent arrhythmic syncope may benefit from pacemaker implantation; the use of implantable defibrillators is controversial
- Gabapentin or pregabalin is useful for neuropathic pain
- Nutritional support is important to ensure adequate caloric intake (nutritional status assessment should be performed)
- Organ transplant can be considered:
  ✓ in patients with irreversible, end-stage organ dysfunction despite complete hematologic response (assessment of minimal residual disease can be considered in these patients)
  ✓ cardiac transplant followed by effective chemotherapy in young patients with isolated severe cardiac involvement

**Figure 3. Supportive therapy in AL amyloidosis.** Supportive measures have a fundamental role in the management of AL amyloidosis, with the goal of improving quality of life, relieving symptoms, and sustaining organ function while anti-PC therapy is delivered and takes effect. The mainstay of supportive treatment is diuretic therapy. However, in amyloidosis, cardiac function is preload dependent, and it is important to avoid reduction of intravascular volume. Angiotensin-converting enzyme inhibitors are generally poorly tolerated because of hypotension: they should be used at the lowest possible dose and discontinued if not well tolerated. Transplantation of the organs involved by amyloidosis may render patients with advanced disease eligible for aggressive specific treatment. The main concerns with organ transplantation are occurrence of amyloidosis in the graft and progression in other organs. However, the availability of effective anti-PC treatments allows for consideration of heart transplantation followed by effective chemotherapy in young patients with isolated severe cardiac involvement. Patients who have advanced, irreversible organ damage, despite achievement of complete HR, can also be considered for transplantation of the organs involved. However, early reports still await confirmation suggest that patients who fail to attain organ response despite having achieved complete HR may have persistent minimal residual clonal disease. In these subjects, further chemotherapy, if deliverable, may lead to minimal residual disease negativity and improvement of organ dysfunction. Implantation of left ventricular assist devices is technically feasible for patients with severe heart failure caused by advanced cardiac amyloidosis, but the possible benefit is unclear.

- Be ready to change treatment approach based on early assessment of hematologic response.
- Patients should be addressed to referral centers.
- Tissue typing with adequate technology cannot be omitted.
- Searching for a monoclonal component should not be delayed.
- Nutritional support is important to ensure adequate caloric intake (nutritional status assessment should

**Figure 4. Common pitfalls in the management of patients with AL amyloidosis.** A presymptomatic biomarker-based diagnosis is possible in patients at risk (subjects with MGUS and abnormal FLC ratio). Treating patients at early stages facilitates the access to effective therapies and can improve survival. The diagnostic pathways for AL and non-AL amyloidosis are different and the choice depends on the presence of a monoclonal component. AL amyloidosis progresses more rapidly, but available treatments can rapidly reverse the course of the disease. The diagnosis of AL amyloidosis should not be delayed. Positive cardiac scintigraphy with bone tracers is not enough to establish a diagnosis of ATTR amyloidosis in a patient with a monoclonal component. Uncharacterized amyloid deposits on a tissue biopsy in a patient with a monoclonal component are not enough to establish a diagnosis of AL amyloidosis. Prespecified treatment duration and/or number of cycles should be avoided in AL amyloidosis. The goal is rapid and deep HR and if it is not reached, rescue therapy is needed. Organ response can sometimes be delayed.
performed in a portion of the study showed a remarkable 96% overall HR rate.29 The randomized trial preliminary results indicate that addition of daratumumab results in significantly higher hematologic (92% vs 77%; CR/VGPR, 79% vs 42%), cardiac (42% vs 22%), and renal (54% vs 27%) response rates across cardiac and renal stages and independent of t(11;14) and prolonged PFS.30

Approximately 20% of patients have advanced (stage IIIb) cardiac involvement at diagnosis. Treatment of these patients remains an unmet need. However, if a profound response is reached within 1 month, OS can improve, even in these subjects.31 Ideally, these patients need a very rapidly acting, safe regimen. The safety profile and rapidity of action of subcutaneous daratumumab make this agent appealing in this setting, and a phase 2 trial is under way (#NCT04131309). Supportive therapy is vital to sustaining organ function while chemotherapy is delivered (Figure 3).

**Treatment of relapsed/refractory disease**

Patients who do not attain satisfactory response should be shifted to second-line treatment as early as possible. So far, there is no evidence to support maintenance therapy in responders, who should be closely followed. However, there is no consensus on when treatment should be started at relapse. We lack validated hematologic progression criteria, and the definition of PFS varies in different studies. Organ progression criteria predict shorter patient and renal survival and such progression should not be awaited before starting rescue therapy.12,17 In general, organ progression is preceded by FLC increases, which can be small and should not be disregarded.32 Other factors to be considered are FLC level and severity of organ involvement at diagnosis, as well as the quality of response to previous treatment.

The mainstay of rescue therapy is IMiDs that can overcome resistance to alkylating agents and proteasome inhibitors, with an OS benefit in responders. In a pooled analysis of patients enrolled in 2 phase 2 clinical trials of lenalidomide and 1 of pomalidomide, 39% of patients achieved VGPR or CR.33 In a real-world European study of pomalidomide, overall HR rate was 44% (CR, 3%; VGPR, 23%).34 Treatment with IMiDs interferes with cardiac response assessment, being associated with NT-proBNP increase, and worsening renal failure can be observed in patients with proteinuria. A phase 3 study compared the oral proteasome inhibitor ixazomib with physician's best choice (lenalidomide in 57% of patients) in relapsed/refractory AL amyloidosis.35 The study failed to meet its primary end point, an improvement in overall HR rate (53% vs 51%), but CR rate was higher (26% vs 18%) and PFS longer in ixazomib-treated patients. Ixazomib can be safely combined with lenalidomide and dexamethasone in an all-oral regimen.36

Non-IMiD–based rescue has recently been evaluated. A phase 2 study reported a 57% HR rate (CR 11%) with bendamustine+ dexamethasone.37 In the past few months, 2 phase 2 trials and numerous retrospective series have addressed the efficacy of daratumumab–based regimens in relapsed/refractory disease. Sanchorawala et al observed a remarkable 90% response rate (CR 41%) in a phase 2 single-agent trial of daratumumab.38 Cardiac and renal response rates were also high (50% and 67%, respectively).38 In a European trial, 55% of patients responded to daratumumab (CR 8%), with lower cardiac (25%) and renal (31%) response rates.39 Notably, in this trial, >50% of patients had not achieved VGPR or better with previous lines of therapy.39 Close monitoring revealed that most HRs occurred after the first daratumumab infusion.38,39 The largest retrospective study included 168 patients treated with daratumumab alone or combined with bortezomib.40 There was no significant difference in outcome with the 2 regimens, and overall HR rate was −65% (CR/VGPR −50%).41 Interestingly, shorter PFS was observed in patients with nephrotic syndrome.42 Combination of daratumumab with IMiDs is particularly interesting in relapsed/refractory disease, and several clinical trials are under way.

**Conclusion**

Despite late recognition of symptoms and delayed referral to a specialized center, the patient described herein benefited from sequential treatment with powerful and rapidly acting regimens guided by biomarker-based risk stratification and monitoring. General practitioners, cardiologists, and nephrologists should be able to recognize symptoms early and to suggest appropriate testing (first, search for a monoclonal component) that can direct patients to the diagnostic pathways of AL or non-AL amyloidosis. Hematologists are in the unique position of recognizing and treating presymptomatic patients. Common pitfalls in the management of patients with AL amyloidosis are reported in Figure 4.

After many years without positive controlled studies, in the past few months, 3 phase 3 trials have been published.28,30,35 Daratumumab combined with bortezomib emerged as a new standard of care. Yet, therapeutic innovation left old questions unanswered and opened new ones. A standard of care for high-risk patients is lacking, and the role of maintenance must be clarified, as well as the positioning of ASCT in the new scenario. A validated definition of hematologic progression would be useful in patient care and in the design of future trials. Further advancements in anti-PC therapy is likely to be based on depth of response, and validation of MS-based detection of monoclonal components and of MRD assessment is warranted to establish optimal goals of therapy. Newer anti-PC approaches, including CAR-T cells and antibody drug conjugates are being considered. Exploration of additional treatment targets, such as interference with LC toxicity by LC stabilizers or doxycycline, which may also target amyloid deposits and is currently undergoing testing in a randomized trial (#NCT03474458), should not be abandoned.

**Authorship**

Contribution: G.P., P.M., and G.M. wrote the manuscript.

Conflict-of-interest disclosure: G.P. has received honoraria and serves on the advisory board of Janssen-Cilag and has received travel grants from Celgene. P.M. has received honoraria as a speaker for Pfizer and Janssen-Cilag and travel support from Celgene. G.M. reports no competing financial interests. Off-label drug use: None disclosed.

Correspondence: Giovanni Palladini, Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy; e-mail: giovanni.palladini@unipv.it.

**Footnotes**

Submitted 8 June 2020; accepted 1 September 2020; prepublished online on Blood First Edition 2 December 2020. DOI 10.1182/blood.2020006913.
REFERENCES


